uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Publications (10 of 93) Show all publications
Takeuchi, M., Kobayashi, T., Biss, T., Kamali, F., Vear, S., Ho, R., . . . Ito, S. (2018). Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis. Paper presented at 119th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) - Breaking Down Barriers to Effective Patient Care, MAR 21-24, 2018, Orlando, FL. Clinical Pharmacology and Therapeutics, 103(S1), S52-S52
Open this publication in new window or tab >>Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis
Show others...
2018 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 103, no S1, p. S52-S52Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
John Wiley & Sons, 2018
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-348313 (URN)10.1002/cpt.993 (DOI)000424997100183 ()
Conference
119th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) - Breaking Down Barriers to Effective Patient Care, MAR 21-24, 2018, Orlando, FL
Available from: 2018-04-25 Created: 2018-04-25 Last updated: 2018-04-25Bibliographically approved
Wadelius, M., Eriksson, N., Smedje, H., Yue, Q.-Y. -., Magnusson, P. K. & Hallberg, P. (2018). Genome‐Wide Association Study of Pandemrix‐Induced Narcolepsy in Sweden – A Possible Role for Glial Derived Neurotrophic Factor (GDNF). Paper presented at First Nordic Conference on Personalized Medicine (NORPM 2018), May 30th ‐ June 1st 2018, Nyborg, Denmark.. Basic & Clinical Pharmacology & Toxicology, 123(S1), 12-13
Open this publication in new window or tab >>Genome‐Wide Association Study of Pandemrix‐Induced Narcolepsy in Sweden – A Possible Role for Glial Derived Neurotrophic Factor (GDNF)
Show others...
2018 (English)In: Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, E-ISSN 1742-7843, Vol. 123, no S1, p. 12-13Article in journal, Meeting abstract (Other academic) Published
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-362656 (URN)10.1111/bcpt.13020 (DOI)000434060000033 ()
Conference
First Nordic Conference on Personalized Medicine (NORPM 2018), May 30th ‐ June 1st 2018, Nyborg, Denmark.
Note

Meeting Abstract: NorPM-O5

Available from: 2018-10-16 Created: 2018-10-16 Last updated: 2018-10-16Bibliographically approved
Wadelius, M., Eriksson, N., Kreutz, R., Bondon-Guitton, E., Ibañez, L., Carvajal, A., . . . Hallberg, P. (2018). Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.. Clinical Pharmacology and Therapeutics, 103(5), 843-853
Open this publication in new window or tab >>Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.
Show others...
2018 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 103, no 5, p. 843-853Article in journal (Refereed) Published
Abstract [en]

Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease. We performed a genome‐wide association study comprising 9,380,034 polymorphisms and 180 HLA alleles in 36 cases of sulfasalazine‐induced agranulocytosis and 5,170 population controls. Sulfasalazine‐induced agranulocytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to HLA‐B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P = 2.55 × 10−8). We HLA‐sequenced a second cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA‐B*08:01, OR = 2.25 (95% CI (1.02, 4.97) P = 0.0439), in particular the HLA‐B*08:01 haplotype HLA‐DQB1*02:01‐DRB1*03:01‐B*08:01‐C*07:01, OR = 3.79 (95% CI (1.63, 8.80) P = 0.0019), and with HLA‐A*31:01, OR = 4.81 (95% CI (1.52, 15.26) P = 0.0077). The number needed to test for HLA‐B*08:01 and HLA‐A*31:01 to avoid one case was estimated to be 1,500. We suggest that intensified monitoring or alternative treatment should be considered for known carriers of HLA‐B*08:01 or HLA‐A*31:01.

National Category
Clinical Laboratory Medicine
Research subject
Clinical Pharmacology
Identifiers
urn:nbn:se:uu:diva-342623 (URN)10.1002/cpt.805 (DOI)000430118300025 ()28762467 (PubMedID)
Projects
Farmakogenomik
Funder
Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceSwedish Research Council, 521-2014-3370; 521-2011-2440Swedish Heart Lung Foundation, 20120557; 20140291
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-06-19Bibliographically approved
Siddiqui, M. K., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., . . . Palmer, C. N. A. (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 38(48), 3569-U31
Open this publication in new window or tab >>A common missense variant of LILRB5 is associated with statin intolerance and myalgia
Show others...
2017 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 38, no 48, p. 3569-U31Article in journal (Refereed) Published
Abstract [en]

Aims: A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained from electronic medical records in the GoDARTS study.

Methods and results: In the GoDARTS cohort, the LILRB5 Asp247 variant was associated with statin intolerance (SI) phenotypes; one defined as having raised CK and being non-adherent to therapy [odds ratio (OR) 1.81; 95% confidence interval (CI): 1.34–2.45] and the other as being intolerant to the lowest approved dose of a statin before being switched to two or more other statins (OR 1.36; 95% CI: 1.07–1.73). Those homozygous for Asp247 had increased odds of developing both definitions of intolerance. Importantly the second definition did not rely on CK elevations. These results were replicated in adjudicated cases of statin-induced myopathy in the PREDICTION-ADR consortium (OR1.48; 95% CI: 1.05–2.10) and for the development of myalgia in the JUPITER randomized clinical trial of rosuvastatin (OR1.35, 95% CI: 1.10–1.68). A meta-analysis across the studies showed a consistent association between Asp247Gly and outcomes associated with SI (OR1.34; 95% CI: 1.16–1.54).

Conclusion: This study presents a novel immunogenetic factor associated with statin intolerance, an important risk factor for cardiovascular outcomes. The results suggest that true statin-induced myalgia and non-specific myalgia are distinct, with a potential role for the immune system in their development. We identify a genetic group that is more likely to be intolerant to their statins.

Keywords
Statins, Pharmacogenetics, Immunogenetics, Precision medicine, Adverse drug reactions, Myalgia
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-339765 (URN)10.1093/eurheartj/ehx467 (DOI)000418697400011 ()29020356 (PubMedID)
Funder
EU, FP7, Seventh Framework Programme, 602108Wellcome trust, 099177/Z/12/Z; 072960; 084726AstraZenecaSwedish Research Council, 521-2011-2440; 521-2014-3370Swedish Heart Lung Foundation, 20120557; 20140291
Available from: 2018-02-02 Created: 2018-02-02 Last updated: 2018-02-02Bibliographically approved
Rasmussen, E. R., von Buchwald, C., Wadelius, M., Prasad, S. C., Kamaleswaran, S., Ajgeiy, K. K., . . . Bygum, A. (2017). Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema. International Journal of Otolaryngology, 2017, Article ID 1476402.
Open this publication in new window or tab >>Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema
Show others...
2017 (English)In: International Journal of Otolaryngology, ISSN 1687-9201, E-ISSN 1687-921X, Vol. 2017, article id 1476402Article in journal (Refereed) Published
Abstract [en]

Objective. To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibitor induced angioedema withregard to demographics, risk factors, family history of angioedema, hospitalization, airway management, outcome, and use ofdiagnostic codes used for the condition.

Study Design. Cohort study.

Methods.This was a retrospective cohort study of 105 patientswith angiotensin converting enzyme-inhibitor induced angioedema in the period 1995–2014.

Results. The cohort consisted of 67females and 38 males (F :Mratio 1.8), with a mean age of 63 [range 26–86] years. Female gender was associated with a significantlyhigher risk of angiotensin converting enzyme-inhibitor induced angioedema. 6.7% had a positive family history of angioedema.Diabetes seemed to be a protective factor with regard to angioedema. 95% experienced angioedema of the head and neck. 4.7%needed intubation or tracheostomy. 74 admissions took place during the study period with a total of 143 days spent in the hospital.The diagnosis codes most often used for this condition were “DT783 Quincke’s oedema” and “DT78.4 Allergy unspecified”.Complement C1 inhibitor was normal in all tested patients.

Conclusion. Female gender predisposes to angiotensin convertingenzyme-inhibitor induced angioedema, whereas diabetes seems to be a protective factor.

National Category
Otorhinolaryngology
Research subject
Pharmacology
Identifiers
urn:nbn:se:uu:diva-342586 (URN)10.1155/2017/1476402 (DOI)28286522 (PubMedID)
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-03-15Bibliographically approved
Nicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., . . . Daly, A. K. (2017). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology, 152(5), 1078-1089
Open this publication in new window or tab >>Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study
Show others...
2017 (English)In: Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012, Vol. 152, no 5, p. 1078-1089Article in journal (Refereed) Published
Abstract [en]

BACKGROUND & AIMS: We performed a genome-wide association study (GWAS) to identify genetic risk factors for druginduced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. METHODS: We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls. The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America. For the GWAS, we included only cases with patients of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. After the discovery analysis was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI associated with various drugs. RESULTS: We associated DILI with rs114577328 (a proxy for A* 33: 01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9 - 3.8; P = 2.4 x 10(-8)) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6 - 2.5; P = 9.7 x 10(-9)). The association with A* 33: 01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the association between DILI and A* 33: 01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was associated with cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6 - 2.7; P = 4.8 x 10(-9)). We did not associate any specific drug classes with genetic polymorphisms, except for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0 - 9.5; P = 7.1 x 10(-9)). We validated the association between A* 33: 01 terbinafine-and sertraline-induced DILI. We could not validate the association between DILI and rs72631567, rs28521457, or rs116561224. CONCLUSIONS: In a GWAS of persons of European descent with DILI, we associated HLA-A* 33: 01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified polymorphisms that appear to be associated with DILI from statins, as well as 2 non-drug-specific risk factors.

Place, publisher, year, edition, pages
W B SAUNDERS CO-ELSEVIER INC, 2017
Keywords
Medication, Liver Damage, Side Effect, Anti-Fungal Agent
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-320025 (URN)10.1053/j.gastro.2016.12.016 (DOI)000397297700035 ()28043905 (PubMedID)
Funder
NIH (National Institute of Health), U01-DK065176 U01-DK065201 U01-DK065184 U01-DK065211 U01DK065193 U01-DK065238 U01-DK083023 U01-DK083027 U01-DK082992 U01-DK083020 U01-DK100928EU, European Research Council, QLRI-CT-2002-02757Swedish Society of Medicine, 2008-21619Swedish Research Council, 521-2011-2440Swedish Heart Lung Foundation, 20120557
Available from: 2017-04-13 Created: 2017-04-13 Last updated: 2017-11-29Bibliographically approved
Siddiqui, M. K., Veluchamy, A., Maroteau, C., Tavendale, R., Carr, F., Pearson, E., . . . Palmer, C. N. (2017). CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 10(4), Article ID e001737.
Open this publication in new window or tab >>CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia
Show others...
2017 (English)In: Circulation: Cardiovascular Genetics, ISSN 1942-325X, E-ISSN 1942-3268, Vol. 10, no 4, article id e001737Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Glu83Gly (rs11559024) with constitutive creatine phosphokinase (CK) levels, CK variation, and inducibility. Given the diagnostic importance of CK in determining muscle damage, we tested the association of the variant with myalgia.

METHODS AND RESULTS: ) lower for carriers of the variant, respectively. The variant was not associated with myalgia (odds ratio, 0.84; 95% confidence interval, 0.52-1.38).

CONCLUSIONS: This study highlights that a genetic factor known to be associated with constitutive CK levels is also associated with CK variability and inducibility. This is discussed in the context of evidence to suggest that the variant has an impact on inducibility of CK by trauma through a previously reported case of a homozygous carrier. However, the lack of association between the variant and myalgia suggests that it cannot reliably be used as a biomarker for muscle symptoms.

Keywords
creatine kinase, diabetes mellitus, genetics, muscles, myalgia, statins
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-342622 (URN)10.1161/CIRCGENETICS.117.001737 (DOI)000407206100012 ()28790154 (PubMedID)
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-09-24Bibliographically approved
Johnson, J., Caudle, K., Gong, L., Whirl-Carrillo, M., Stein, C., Scott, S., . . . Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 102(3), 397-404
Open this publication in new window or tab >>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
Show others...
2017 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 102, no 3, p. 397-404Article, review/survey (Refereed) Published
Abstract [en]

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-342581 (URN)10.1002/cpt.668 (DOI)000407082400015 ()
Funder
Swedish Research Council, 521-2011-2440Swedish Research Council, 521-2014-3370Swedish Heart Lung Foundation, 20120557Swedish Heart Lung Foundation, 20140291
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-04-05Bibliographically approved
Gottlieb, A., Daneshjou, R., DeGorter, M., Bourgeois, S., Svensson, P., Wadelius, M., . . . Altman, R. (2017). Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans. Genome Medicine, 9(1), Article ID 98.
Open this publication in new window or tab >>Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans
Show others...
2017 (English)In: Genome Medicine, ISSN 1756-994X, E-ISSN 1756-994X, Vol. 9, no 1, article id 98Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Genome-wide association studies are useful for discovering genotype-phenotype associations but are limited because they require large cohorts to identify a signal, which can be population-specific. Mapping genetic variation to genes improves power and allows the effects of both protein-coding variation as well as variation in expression to be combined into "gene level" effects.

METHODS: Previous work has shown that warfarin dose can be predicted using information from genetic variation that affects protein-coding regions. Here, we introduce a method that improves dose prediction by integrating tissue-specific gene expression. In particular, we use drug pathways and expression quantitative trait loci knowledge to impute gene expression-on the assumption that differential expression of key pathway genes may impact dose requirement. We focus on 116 genes from the pharmacokinetic and pharmacodynamic pathways of warfarin within training and validation sets comprising both European and African-descent individuals.

RESULTS: We build gene-tissue signatures associated with warfarin dose in a cohort-specific manner and identify a signature of 11 gene-tissue pairs that significantly augments the International Warfarin Pharmacogenetics Consortium dosage-prediction algorithm in both populations.

CONCLUSIONS: Our results demonstrate that imputed expression can improve dose prediction and bridge population-specific compositions.

MATLAB code is available at https://github.com/assafgo/warfarin-cohort.

Keywords
African Americans, International Warfarin Pharmacogenetics Consortium, Pharmacogenomics, Warfarin dose
National Category
Dentistry
Identifiers
urn:nbn:se:uu:diva-224501 (URN)10.1186/s13073-017-0495-0 (DOI)000416455600001 ()29178968 (PubMedID)
Funder
Swedish Research Council, Medicine 521-2011-2440Swedish Heart Lung Foundation, 20120557Swedish Heart Lung Foundation, 20140291Swedish Research Council, 521-2014-3370
Available from: 2014-05-14 Created: 2014-05-13 Last updated: 2018-03-16Bibliographically approved
Hallberg, P., Nagy, J., Karawajczyk, M., Nordang, L., Islander, G., Norling, P., . . . Wadelius, M. (2017). Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough. The Annals of Pharmacotherapy, 51(4), 293-300
Open this publication in new window or tab >>Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough
Show others...
2017 (English)In: The Annals of Pharmacotherapy, ISSN 1060-0280, E-ISSN 1542-6270, Vol. 51, no 4, p. 293-300Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Angioedema is a rare and serious adverse drug reaction (ADR) to angiotensin-converting enzyme (ACE) inhibitor treatment. Dry cough is a common side effect of ACE inhibitors and has been identified as a possible risk factor for angioedema.

OBJECTIVE: We compared characteristics between patients with ACE inhibitor-induced angioedema and cough with the aim of identifying risk factors that differ between these adverse events.

METHODS: Data on patients with angioedema or cough induced by ACE inhibitors were collected from the Swedish database of spontaneously reported ADRs or from collaborating clinicians. Wilcoxon rank sum test, Fisher's exact test, and odds ratios (ORs) with 95% CIs were used to test for between-group differences. The significance threshold was set to P <0.00128 to correct for multiple comparisons.

RESULTS: Clinical characteristics were compared between 168 patients with angioedema and 121 with cough only. Smoking and concomitant selective calcium channel blocker treatment were more frequent among patients with angioedema than cough: OR = 4.3, 95% CI = 2.1-8.9, P = 2.2 × 10(-5), and OR = 3.7, 95% CI = 2.0-7.0, P = 1.7 × 10(-5). Angioedema cases were seen more often in male patients (OR = 2.2, 95% CI = 1.4-3.6, P = 1.3 × 10(-4)) and had longer time to onset and higher doses than those with cough ( P = 3.2 × 10(-10) and P = 2.6 × 10(-4)). A multiple model containing the variables smoking, concurrent calcium channel blocker treatment, male sex, and time to onset accounted for 26% of the variance between the groups.

CONCLUSION: Smoking, comedication with selective calcium channel blockers, male sex, and longer treatment time were associated with ACE inhibitor-induced angioedema rather than cough.

Keywords
ACE inhibitors, adult medicine, adverse drug reactions, calcium-channel blockers, clinical pharmacology, drug safety, interactions, medication safety, pulmonary
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-316913 (URN)10.1177/1060028016682251 (DOI)000396799400003 ()27889699 (PubMedID)
Funder
Swedish Research CouncilSwedish Heart Lung Foundation
Available from: 2017-03-08 Created: 2017-03-08 Last updated: 2018-02-01Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-6368-2622

Search in DiVA

Show all publications